Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia H2’25: Green shoots on the clinical side

AIFORIA16.03.2026, 10.29
Antti Siltanen, Isa Hudd
Discuss

Aiforia’s H2 revenue growth originated in Europe, where the company has successfully promoted the adoption of clinical models. The digital pathology market has developed more slowly than expected, and the investment's risk profile remains high. Analyst Antti Siltanen summarizes.

Stay up to date
Analyst Interviews

Upcoming webcasts

Recent videos

HCA Morgenbørs 07/09 - ChemoMetec i fokus i interview med Tobias Friis og udsigt til faldende markeder
07.09.2026, 09.21 ChemoMetec
HCA Morgenbørs 04/09 - Johannes Møller interview og fokus på jobmarkedsrapport
04.09.2026, 10.26 A.P. Møller - Mærsk
HCA Morgenbørs 03/09 - Jakob Have interview og stilstand i oliepris og renter
03.09.2026, 11.09 Donkey Republic
Clas Ohlson AB, Q1'26
03.09.2026, 09.00 Clas Ohlson
HCA Morgenbørs 02/09 - Novo Nordisk vs. Eli Lilly med Claus Johansen og dagens aktiemarked
02.09.2026, 09.31 Novo Nordisk
View all videos